CCMW
ACHN

Cypress Capital Management (Wyoming)’s Achillion Pharmaceuticals ACHN Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,000
Closed -$4K – 210
2019
Q3 		$4K Buy
+1,000
New +$3.85K ﹤0.01% 172

Other funds holding ACHN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s ACHN Position: Q4 2019 in Review

Cypress Capital Management (Wyoming) sold out of Achillion Pharmaceuticals (ACHN) in Q4 2019, closing a stake of 1,000 shares — an estimated $4K sold.

Cypress Capital Management (Wyoming) first reported a position in ACHN in Q3 2019 and held it in 1 quarter. The position peaked at $4K in Q3 2019. 132 funds tracked by Wall St. Rank hold ACHN as of Q4 2019.

  • Cypress Capital Management (Wyoming) reported no remaining Achillion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Cypress Capital Management (Wyoming) sold 1,000 Achillion Pharmaceuticals shares in Q4 2019, an estimated $4K.
  • Cypress Capital Management (Wyoming) first reported a position in Achillion Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Cypress Capital Management (Wyoming)'s Achillion Pharmaceuticals position peaked at $4K in Q3 2019.
  • 132 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2019.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q4 2019, filed 3 Feb 2020.